Avidity Biosciences (RNAM)

Executive Summary

Avidity Biosciences is pioneering a novel class of targeted RNA therapeutics through its proprietary Antibody Oligonucleotide Conjugate (AOC) platform, which enables precise delivery of oligonucleotides to muscle cells via antibody targeting. The company's lead programs address severe muscle diseases with high unmet need: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). With multiple Phase 3 and Phase 2 trials underway, Avidity aims to validate its platform and bring the first AOC-based therapies to market. Avidity's most advanced program, del-desiran (AOC 1001) for DM1, is in Phase 3 with top-line data expected from a pivotal trial (NCT06411288) in late 2026. A large Phase 3 trial for AOC 1020 in FSHD is also recruiting, and AOC 1044 is advancing in Phase 2 for DMD patients amenable to exon 44 skipping. Positive data from any of these programs could represent a significant milestone for the company and the AOC platform. Avidity's robust pipeline, strong preclinical proof-of-concept, and proprietary delivery technology position it as a leader in targeted RNA therapies for muscle disorders.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 top-line data for del-desiran (AOC 1001) in DM165% success
• H1 2027Phase 3 enrollment completion or interim data for AOC 1020 in FSHD60% success
• Q3 2026Phase 2 interim data for AOC 1044 in DMD (exon 44)50% success